CN113329736B - Self-emulsifying oral preparation of terpene medicinal composition, its preparation method and application - Google Patents

Self-emulsifying oral preparation of terpene medicinal composition, its preparation method and application Download PDF

Info

Publication number
CN113329736B
CN113329736B CN201980087982.3A CN201980087982A CN113329736B CN 113329736 B CN113329736 B CN 113329736B CN 201980087982 A CN201980087982 A CN 201980087982A CN 113329736 B CN113329736 B CN 113329736B
Authority
CN
China
Prior art keywords
self
emulsifying
limonene
emulsifier
pinene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980087982.3A
Other languages
Chinese (zh)
Other versions
CN113329736A (en
Inventor
沈芳玲
赵家欣
聂红梅
韩悦
石江林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Grand Johamu Pharmaceutical Co Ltd
Original Assignee
Beijing Grand Johamu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Grand Johamu Pharmaceutical Co Ltd filed Critical Beijing Grand Johamu Pharmaceutical Co Ltd
Publication of CN113329736A publication Critical patent/CN113329736A/en
Application granted granted Critical
Publication of CN113329736B publication Critical patent/CN113329736B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A terpene pharmaceutical composition self-emulsifying oral preparation, its preparation method and application, the said self-emulsifying oral preparation includes the pharmaceutical composition of eucalyptol, limonene and alpha-pinene of the specific proportion and emulsifier, optional grease and auxiliary emulsifier, cooperate with each other among every component, make the terpene pharmaceutical composition self-emulsifying liquid medicine nature made stable, homogeneous, have improved the quality stability of the terpene pharmaceutical composition self-emulsifying oral preparation, has guaranteed the therapeutic effect of the medicament, suitable for clinical large-area popularization and use.

Description

Self-emulsifying oral preparation of terpene medicinal composition, preparation method and application
PRIORITY INFORMATION
This application requests priority and benefit of a patent application with patent application number 201910036486.7 filed on day 1, month 15 of 2019 with the chinese national intellectual property office and is incorporated herein by reference in its entirety.
Technical Field
The invention relates to the technical field of pharmaceutical preparations, and relates to a self-emulsifying oral preparation of a terpene pharmaceutical composition, a preparation method and application thereof.
Background
The pharmaceutical composition containing eucalyptol, limonene and alpha-pinene can be used for relieving cough, diminishing inflammation, eliminating phlegm and promoting the discharge of contrast medium for respiratory disease patients, and can be used as an aerosol inhalation for improving the functional damage of mucociliary clearance system caused by rhinitis and nasosinusitis, for example, the prior art discloses a pharmaceutical composition fat emulsion injection containing eucalyptol, limonene and alpha-pinene and a preparation method thereof, wherein the injection comprises 0.0128-0.032% of eucalyptol, 0.0084-0.0210% of limonene, 0.0028-0.0070% of alpha-pinene, 10-30% of soybean oil for injection, 1.0-1.5% of yolk lecithin for injection or 0.8-1.5% of soybean phospholipid for injection, 2.0-2.5% of glycerol for injection and 100mL of water for injection, the injection has various effects of diluting sputum, promoting accelerated movement and anti-inflammatory of trachea and bronchus cilia, does not contain sugar, is suitable for patients with stomach diseases and is not suitable for patients in clinical use, but is suitable for emergency treatment because of patients, is not convenient for emergency treatment, but is expensive in clinical use. Therefore, there is a need to develop an oral formulation of a pharmaceutical composition comprising eucalyptol, limonene and alpha-pinene.
Self-emulsifying drug delivery systems (SEDDS) are homogeneous, clear, homogeneous solutions composed of an oil solution and a surfactant, and sometimes including a cosolvent. The system spontaneously forms an oil-in-water emulsion in the aqueous phase of gastric juice after oral administration due to gastric motility and the presence of an emulsifier. Compared with emulsion, SEDDS belongs to a thermodynamic stable system, and has the advantages of simple process, stable property and convenient storage. In addition, the self-emulsifying preparation is convenient to administer, can be prepared into various administration forms such as capsules, tablets, pellets and the like, is accurate in dosage and convenient to take, is suitable for large-scale production, and has great development prospect and application value.
However, eucalyptol, limonene and alpha-pinene are three different substances with certain differences in properties, self-emulsifying liquid medicine of terpene pharmaceutical compositions containing eucalyptol, limonene, alpha-pinene and the like prepared by using a surfactant and/or a cosolvent in the prior art is unstable and easy to generate layering phenomenon, and a large amount of non-emulsified oil drops of the medicine exist on the surface when the self-emulsifying liquid medicine is dispersed in water, so that uniform liquid medicine is difficult to form, the quality of a self-emulsifying preparation of the pharmaceutical composition is unstable, and the large-area popularization and application of the self-emulsifying liquid medicine are greatly limited.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to overcome the defect of unstable preparation quality of the oral preparation of the pharmaceutical composition containing eucalyptol, limonene and alpha-pinene prepared by the existing method, so as to provide the self-emulsifying oral preparation of the terpene pharmaceutical composition. Meanwhile, the invention also provides a preparation method and application of the self-emulsifying oral preparation of the terpene pharmaceutical composition.
In order to solve the technical problems, the invention provides a self-emulsifying oral preparation. According to an embodiment of the invention, the self-emulsifying oral formulation comprises: active ingredients including eucalyptol, limonene and alpha-pinene; and a pharmaceutical carrier. The self-emulsifying oral preparation provided by the embodiment of the invention has the advantages of high stability, narrow particle size distribution range, fast drug absorption, high oral bioavailability and small gastrointestinal adverse reaction.
According to an embodiment of the present invention, the self-emulsifying oral formulation may further comprise at least one of the following additional technical features:
according to an embodiment of the invention, the self-emulsifying oral formulation comprises: 40 to 65 parts by weight of the eucalyptol; 25 to 45 parts by weight of the limonene; and 5 to 20 parts by weight of the alpha-pinene.
According to the embodiment of the invention, the weight ratio of the active ingredient to the drug carrier is (1-15): 10.
According to the embodiment of the invention, the weight ratio of the active ingredient to the drug carrier is (1-6): 10.
According to the embodiment of the invention, the weight ratio of the active ingredient to the drug carrier is (1-5): 10.
According to the embodiment of the invention, the weight ratio of the active ingredient to the drug carrier is (5-6): 10. The inventor finds that the weight ratio of the active ingredient to the drug carrier is (5-6): 10, the stability of the self-emulsifying oral preparation is further improved, the dispersed particle size in water is further reduced, the drug absorption is better, and the gastrointestinal reaction is further reduced.
According to an embodiment of the invention, the weight ratio of the active ingredient to the pharmaceutical carrier is 5.4.
According to an embodiment of the invention, the drug carrier comprises: an emulsifier; optionally a grease; and optionally a co-emulsifier.
According to an embodiment of the present invention, the emulsifier comprises at least one selected from tween, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, phospholipid, caprylic capric polyglycol ester.
According to an embodiment of the invention, the phospholipids comprise soy phospholipids.
According to an embodiment of the present invention, the oil or fat includes at least one selected from the group consisting of soybean oil, medium chain triglyceride, ethyl oleate, corn oil, and olive oil.
According to an embodiment of the present invention, the co-emulsifier comprises at least one selected from the group consisting of ethanol, 1, 2-propanediol, glycerol, polyethylene glycol, diethylene glycol monoethyl ether.
According to an embodiment of the invention, the drug carrier comprises: 10 to 50 parts by weight of the oil; 40 to 80 parts by weight of the emulsifier; and 5-30 parts by weight of the coemulsifier.
According to an embodiment of the invention, the drug carrier comprises: 10 to 35 parts by weight of the oil; 50 to 70 of said emulsifier; and 10-25 parts by weight of the coemulsifier.
According to an embodiment of the invention, the drug carrier comprises: 25 to 35 parts by weight of said medium chain triglycerides; 50-65 parts by weight of the caprylic/capric polyethylene glycol glyceride; and 10-15 parts by weight of diethylene glycol monoethyl ether.
According to an embodiment of the invention, the pharmaceutical carrier comprises: 0 to 5 parts by weight of the oil; 0 to 5 parts by weight of the co-emulsifier; 90 to 100 parts by weight of the emulsifier. The inventor finds that the dosage of the hydrophilic co-emulsifier is greatly reduced in the dosage range of the components of the drug carrier, so that the layering phenomenon of the concentrated solution is greatly reduced, and meanwhile, the inventor also finds that the dispersion particle size of the concentrated solution in water is greatly reduced, so that the drug absorption is promoted, and the adverse reaction of the gastrointestinal tract is reduced; moreover, the dosage of the grease is greatly reduced, only the oily active ingredients provide oily ingredients of the preparation, the usage of an oil phase is reduced on the basis of ensuring the self-emulsifying effect, and the dosage of auxiliary materials is reduced, so that the preparation is beneficial to being pressed into a smaller preparation form.
According to an embodiment of the invention, the emulsifier consists of at least two emulsifiers.
According to the embodiment of the invention, the emulsifier consists of a first emulsifier and a second emulsifier, the mass fraction of the first emulsifier is 20-80%, and the mass fraction of the second emulsifier is 10-70% based on the total mass of the self-emulsifying oral preparation.
According to an embodiment of the invention, said drug carrier consists of said emulsifier.
According to an embodiment of the present invention, the self-emulsifying oral formulation is in the form of a hard capsule, a soft capsule or a tablet.
According to an embodiment of the invention, the self-emulsifying oral formulation comprises: 18.2g of eucalyptol, 16.4g of limonene, 1.8g of alpha-pinene, 181.8g of soybean oil, 145.4g of tween 80 and 36.4g of propylene glycol; or
73.3g eucalyptol, 33.3g limonene, 26.6g alpha-pinene, 26.7g medium chain triglyceride, 213.4g caprylic capric polyethylene glycol glyceride, 26.7g diethylene glycol monoethyl ether; or
14.6g eucalyptol, 16.4g limonene, 5.4g alpha-pinene, 90.9g medium chain triglyceride, 236.6g caprylic capric polyethylene glycol glyceride, 36.4g diethylene glycol monoethyl ether; or
86.6g of eucalyptol, 40.0g of limonene, 6.6g of alpha-pinene, 93.4g of medium chain triglyceride, 133.4g of caprylic/capric macrogol glyceride, 40g of diethylene glycol monoethyl ether; or
53.3g eucalyptol, 53.3g limonene, 26.6g alpha-pinene, 26.7g ethyl oleate, 160.1g polyoxyethylene castor oil, 80.0g diethylene glycol monoethyl ether; or
78.0g eucalyptol, 36.0g limonene, 6.0g alpha-pinene, 126g corn oil, 140g polyoxyethylene hydrogenated castor oil, 14.0g propylene glycol; or
42.7g of eucalyptol, 28.0g of limonene, 9.3g of alpha-pinene, 80g of soybean oil, 180g of Tween 80 and 60g of PEG-400; or
69.3g of eucalyptol, 45.5g of limonene, 15.2g of alpha-pinene, 40g of corn oil, 170g of polyoxyethylene castor oil and 60g of propylene glycol; or
70.0g of eucalyptol, 45.5g of limonene, 14.5g of alpha-pinene, 40g of soybean oil, 180g of polyoxyethylene hydrogenated castor oil and 50g of propylene glycol; or
70.0g of eucalyptol, 45.5g of limonene, 14.5g of alpha-pinene, 50g of ethyl oleate, 160g of caprylic/capric polyethylene glycol glyceride and 60g of diethylene glycol monoethyl ether; or
69.3g of eucalyptol, 45.5g of limonene, 15.2g of alpha-pinene, 40g of soybean oil, 170g of Tween 80 and 60g of propylene glycol; or
69.3g of eucalyptol, 45.5g of limonene, 15.2g of alpha-pinene, 40g of soybean oil, 170g of Tween 80 and 60g of propylene glycol; or
75g of eucalyptol, 50g of limonene, 16g of alpha-pinene, 79g of Tween 80, and 180g of caprylic/capric macrogol; or
75g of eucalyptol, 50g of limonene, 16g of alpha-pinene, 165g of caprylic/capric polyethylene glycol glyceride and 94g of polyoxyethylene castor oil.
In a second aspect of the invention, the invention provides a process for the preparation of the self-emulsifying oral formulation as hereinbefore described. According to an embodiment of the invention, the method comprises: mixing said active ingredient with said pharmaceutical carrier so as to obtain said self-emulsifying oral formulation.
According to an embodiment of the present invention, the method may further include at least one of the following additional technical features:
according to an embodiment of the invention, further comprising encapsulating the mixture comprising the active ingredient and the pharmaceutical carrier in order to obtain a formulation.
According to an embodiment of the invention, the formulation is a soft capsule, a hard capsule or a tablet.
According to an embodiment of the present invention, mixing the active ingredient with the pharmaceutical carrier further comprises: subjecting the active ingredient and optionally the fat to a first mixing treatment so as to obtain an oil phase mixture; and carrying out second mixing treatment on the oil-phase mixture, the emulsifier and the optional coemulsifier.
According to an embodiment of the present invention, the first mixing process and the second mixing process are each independently performed under the following conditions: the temperature is 15-30 ℃; the stirring speed is as follows: 30-50 rpm; and/or the mixing time is 1 to 2 hours.
According to an embodiment of the invention, the medicament is for the treatment or prevention of a respiratory disease.
According to an embodiment of the invention, the respiratory disease comprises: at least one of acute sinusitis, chronic sinusitis, sinusitis operation inflammation, acute and chronic bronchitis, pneumonia, bronchiectasis, pulmonary abscess, chronic obstructive pulmonary disease, pulmonary fungal infection, pulmonary tuberculosis, and silicosis.
In a third aspect of the invention, a method of treating or preventing a respiratory disorder is presented. According to an embodiment of the invention, the method comprises administering the self-emulsifying oral formulation as described above to a patient with a respiratory disorder. According to the method provided by the embodiment of the invention, the self-emulsifying oral preparation has the advantages of faster absorption, higher oral bioavailability, weaker gastrointestinal reaction of patients and better treatment effect.
According to an embodiment of the present invention, the method may further include at least one of the following additional technical features:
according to an embodiment of the invention, the respiratory disease comprises: at least one of acute sinusitis, chronic sinusitis, sinusitis operation inflammation, acute and chronic bronchitis, pneumonia, bronchiectasis, pulmonary abscess, chronic obstructive pulmonary disease, pulmonary fungal infection, pulmonary tuberculosis, and silicosis.
The technical scheme of the invention has the following advantages:
1. the terpene medicinal composition self-emulsifying oral preparation provided by the invention comprises a medicinal composition of eucalyptol, limonene and alpha-pinene in a specific proportion, grease, an emulsifier and an auxiliary emulsifier, and all the components are matched with each other, so that the prepared terpene medicinal composition self-emulsifying liquid medicine is stable and uniform in property, the quality stability of the terpene medicinal composition self-emulsifying oral preparation is improved, the treatment effect of the medicine is ensured, and the terpene medicinal composition self-emulsifying oral preparation is suitable for large-area clinical popularization and use.
2. The terpene medicinal composition self-emulsifying oral preparation provided by the invention further limits the types and contents of the emulsifying agent and the co-emulsifying agent, improves the uniformity of the self-emulsifying liquid medicine of the terpene medicinal composition, and is beneficial to improving the quality of the self-emulsifying oral preparation.
3. The terpene pharmaceutical composition self-emulsifying oral preparation provided by the invention can spontaneously form an oil-in-water microemulsion in a water phase of gastric juice after oral administration under the action of gastric peristalsis and an emulsifier and an auxiliary emulsifier, effectively cover the taste of eucalyptol, limonene and alpha-pinene, reduce the stimulation of the medicine to the gastrointestinal tract, avoid the occurrence of adverse reactions such as nausea, vomiting, diarrhea and the like, and is suitable for patients with a gastric disease history.
4. The terpene medicine composition self-emulsifying oral preparation provided by the invention enters gastric juice through oral administration, and contacts with water in the gastric juice to form medicine-carrying microemulsion, the medicine composition exists in the tiny oil drops and is rapidly distributed in the whole stomach, the dissolution of the water-insoluble medicine is greatly improved by depending on the huge specific surface area of the tiny oil drops, so that the medicine can more easily pass through a hydration layer of the gastrointestinal wall, the permeability of epithelial cells of the medicine is increased, the absorption of the medicine is promoted, and the problem that the terpene medicine is difficult to absorb in a human body is effectively solved.
5. The terpene pharmaceutical composition self-emulsifying oral preparation provided by the invention comprises eucalyptol, limonene and alpha-pinene which are all natural products, and has the advantages of wide sources, simple process, low cost, definite chemical structure and composition, low toxicity and high safety.
6. The preparation method of the self-emulsifying oral preparation of the terpene pharmaceutical composition provided by the invention has the advantages of simple process, low cost, good stability and controllable quality, can be used for preparing self-emulsifying liquid medicine into oral dosage forms such as soft capsules, hard capsules, tablets, granules, dropping pills or pellets and the like, and is suitable for large-scale batch production.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
The above and/or additional aspects and advantages of the present invention will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
FIG. 1 is a pseudo-ternary phase diagram of the mixed oil phase Tween 80-PEG-400 according to the embodiment of the present invention;
FIG. 2 is a pseudo-ternary phase diagram of mixed oil phase Tween 80-Transcutol according to the embodiment of the invention;
FIG. 3 is a pseudo-ternary phase diagram of a mixed oil phase-Labrasol-PEG 400 according to an embodiment of the present invention;
FIG. 4 is a pseudo-ternary phase diagram of the mixed oil phase Labrasol Transcutol according to an embodiment of the present invention;
FIG. 5 is a pseudo-ternary phase diagram of the oil-free co-emulsifier-eucalyptus oil-emulsifier 1-emulsifier 2 according to an embodiment of the present invention;
fig. 6 is a representative particle size distribution diagram of a self-emulsifying drug solution in accordance with an embodiment of the present invention.
Detailed Description
Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are illustrative only for the purpose of explaining the present invention, and are not to be construed as limiting the present invention.
It should be noted that the terms "first" and "second" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or to implicitly indicate the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Further, in the description of the present invention, "a plurality" means two or more unless otherwise specified.
The invention mainly researches the prescription composition and the preparation process of the self-emulsifying preparation from three parts of preliminary prescription screening, drawing of a pseudo-ternary phase diagram and an orthogonal test to determine the optimal prescription of the self-emulsifying concentrated solution of the pharmaceutical composition.
(1) Preliminary screening of prescriptions
Fixing the formula proportion of the self-emulsifying concentrated solution to be unchanged, respectively preparing the self-emulsifying concentrated solution by using different grease, emulsifiers and co-emulsifiers, and screening the proper grease, emulsifiers and co-emulsifiers according to the self-emulsifying effect.
The formulation for designing the self-emulsifying formulation was:
Figure GDA0003148332200000071
wherein the screened oil comprises soybean oil, corn oil, medium chain triglyceride, and ethyl oleate; the screened emulsifying agent comprises Tween 80, polyoxyethylene castor oil (EL-35), polyoxyethylene hydrogenated castor oil (RH-40), caprylic capric polyethylene glycol glyceride (Labrasol); the screened co-emulsifier includes propylene glycol, glycerol, diethylene glycol monoethyl ether (Transcutol), and PEG-400.
The fixed oil was soybean oil, and the results of screening the types of emulsifiers and co-emulsifiers are shown in table 1.
TABLE 1 preliminary screening results for emulsifiers, coemulsifiers
Figure GDA0003148332200000072
The fixed emulsifier is tween 80, the co-emulsifier is propylene glycol, and the results of screening the grease types are shown in table 2.
TABLE 2 results of screening oil and fat species
Figure GDA0003148332200000073
Figure GDA0003148332200000081
By combining the test results, the common soybean oil is selected as the grease, the Tween 80 and the caprylic/capric polyethylene glycol glyceride with good self-emulsifying effect are used as the emulsifying agents, and the PEG-400 and the diethylene glycol monoethyl ether are used as the auxiliary emulsifying agents for subsequent tests.
In addition, the inventor unexpectedly discovers in experiments that if the dosage of the grease and the co-emulsifier is reduced as much as possible, and the composite emulsifier is adopted, the emulsification rate is greatly improved, and the particle size of emulsion drops is greatly reduced.
Table 3 shows the appearance of the concentrate, the emulsification rate and the emulsion droplet size data after the inventors tried to reduce the amount of grease or co-emulsifier during the experiment.
Table 3:
Figure GDA0003148332200000082
(2) Drawing of pseudo ternary phase diagram
And drawing a pseudo ternary phase diagram of each combined oil phase-emulsifier-co-emulsifier, and determining an effective self-emulsifying area formed by each prescription. The results are shown in FIGS. 1-4 (marked with effective self-emulsifying region), and the mass ratio of the effective self-emulsifying region formed by taking the pseudo-ternary phase diagram of oil phase-Tween 80-PEG-400 (FIG. 1) is oil phase 0.1-0.4, tween 80 0.4-0.9, and PEG-400 0.1-0.6. And selecting a prescription proportion with higher oil phase content for subsequent tests.
In addition, the inventor draws a pseudo ternary phase diagram by using a grease-free auxiliary emulsifier-eucalyptol and pinene oil-emulsifier 1-emulsifier 2, and determines effective self-emulsifying areas formed by each formula, and the result is shown in figure 5. As can be seen from the figure, in the range of the effective self-emulsifying region, the proportion of the eucalyptus and limonene oil is 10-60%, the proportion of the auxiliary material emulsifier 1 is 20-80%, and the proportion of the emulsifier 2 is 10-70%. The ratio of drug to carrier is thus 1: 10 portions of carriers (1.1-15).
(3) Quadrature test
And designing a proper factor level table and an orthogonal test table, and screening an optimal formula of the self-emulsifying concentrated solution through the self-emulsifying rate and the emulsion drop particle size.
The factor levels for designing the orthogonal test are shown in table 4, using the pharmaceutical composition and soybean oil as oil phase, tween 80 as emulsifier, and PEG-400 as co-emulsifier.
TABLE 4 orthogonal test factor horizon
Figure GDA0003148332200000091
The test results are shown in Table 5.
TABLE 5 results of orthogonal tests
Figure GDA0003148332200000092
Figure GDA0003148332200000101
By visual analysis, the optimal formula is 0.30g of oil phase, 0.50g of Tween 80 and 0.15g of PEG-400. The formula is repeated three times, the dispersion rate of the prepared self-emulsifying concentrated solution in water is 20-40 s, and the particle size of emulsion drops is 150-180 nm.
The following examples are provided to better understand the present invention, not to limit the best mode, and not to limit the content and protection scope of the present invention, and any product that is the same or similar to the present invention and is obtained by combining the present invention with other features of the prior art and the present invention falls within the protection scope of the present invention.
The examples do not show the specific experimental steps or conditions, and can be performed according to the conventional experimental steps described in the literature in the field. The reagents or instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially.
In the following examples, eucalyptol, limonene and alpha-pinene may be prepared as follows: the eucalyptol is obtained by rectifying eucalyptus oil (crude oil) prepared from eucalyptus globulus labill of eucalyptus of Myrtaceae, the content of which is 80-85%; squeezing lemon peel of Citrus reticulata Blanco of Citrus of Rutaceae, distilling with steam to obtain lemon oil (crude oil), and rectifying to obtain limonene with content of 93% or more; steam distilling and refining oleoresin exuded from Pinus massoniana of Pinaceae to obtain alpha-pinene with content of more than 90%.
EXAMPLE 1 preparation of terpene pharmaceutical compositions self-emulsifying Soft capsules
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000102
the preparation method comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and soybean oil in the formula amount, stirring at the rotation speed of 50rpm for 1 hour at 15 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding the Tween 80 and the propylene glycol of the prescription amount into the oil phase, stirring at the rotation speed of 50rpm for 1 hour at 15 ℃, and uniformly mixing to form a uniform self-emulsifying liquid medicine;
(3) According to the weight ratio of 1:0.5:1.1 preparing capsule skin by weighing gelatin, glycerol and water;
(4) And (3) pressing the self-emulsifying liquid medicine obtained in the step (2) and the capsule skin obtained in the step (3) on a soft capsule machine in a conventional mode, and setting in a setting machine to prepare the terpene medicinal composition self-emulsifying soft capsule.
EXAMPLE 2 preparation of terpene-based pharmaceutical composition self-emulsifying Soft Capsule
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000111
the preparation method comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and medium-chain triglyceride in the formula amount, stirring for 2 hours at the rotation speed of 30rpm at the temperature of 30 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding Labrasol and Transcutol in the prescription amount into the oil phase, stirring at 30 ℃ and 30rpm for 2 hours, and uniformly mixing to form a uniform self-emulsifying liquid medicine;
(3) Weighing gelatin, glycerol and water according to the weight ratio of 1;
(4) And (3) pressing the self-emulsifying liquid medicine obtained in the step (2) and the capsule skin obtained in the step (3) on a soft capsule machine in a conventional mode, and setting in a setting machine to prepare the terpene medicinal composition self-emulsifying soft capsule.
EXAMPLE 3 preparation of terpene pharmaceutical compositions self-emulsifying Soft capsules
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000112
the preparation method is the same as example 2.
EXAMPLE 4 preparation of terpene-based pharmaceutical composition self-emulsifying Soft Capsule
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000113
Figure GDA0003148332200000121
the preparation method is the same as example 2.
EXAMPLE 5 preparation of terpene pharmaceutical compositions self-emulsifying hard capsules
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000122
the preparation method comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and ethyl oleate in the formula amount, stirring for 2 hours at 20 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding the polyoxyethylene castor oil and the diethylene glycol monoethyl ether in the formula amount into the oil phase, and stirring for 2 hours at 20 ℃ to uniformly mix to form a uniform self-emulsifying liquid medicine;
(3) And (3) dripping the self-emulsifying liquid medicine obtained in the step (2) into micropowder silica gel under the condition of stirring, adding magnesium stearate, and subpackaging into hard capsules to obtain the terpene medicinal composition self-emulsifying hard capsules.
EXAMPLE 6 preparation of terpene-based pharmaceutical composition self-emulsifying tablet
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000123
Figure GDA0003148332200000131
the preparation method comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and corn oil in the formula amount, and stirring for 2 hours at 20 ℃ to be uniformly mixed to obtain an oil phase;
(2) Adding the polyoxyethylene hydrogenated castor oil and propylene glycol of the formula amount into an oil phase, and stirring for 2 hours at 20 ℃ to uniformly mix to form a uniform self-emulsifying liquid medicine;
(3) Dripping the self-emulsifying liquid medicine obtained in the step (2) into superfine silica gel powder under the stirring condition, adding auxiliary materials such as microcrystalline cellulose, spray-dried lactose, magnesium stearate and the like, and preparing the terpene medicinal composition self-emulsifying tablet by adopting a conventional direct tabletting method.
EXAMPLE 7 preparation of terpene pharmaceutical compositions self-emulsifying Soft capsules
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000132
the preparation process comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and soybean oil in the prescription amount, stirring for 1 hour at 20 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding tween 80 and PEG-400 into the oil phase, and stirring for 2 hr at 20 deg.C to obtain self-emulsifying concentrated solution;
(3) Preparing capsule skin by weighing gelatin, glycerol and water according to the weight ratio of 1;
(4) And (3) preparing the self-emulsifying concentrated solution obtained in the step (2) and the capsule shell obtained in the step (3) into soft capsules in a conventional manner.
EXAMPLE 8 preparation of terpene-based pharmaceutical composition self-emulsifying Soft Capsule
The prescription of the self-emulsifying liquid medicine is as follows:
Figure GDA0003148332200000133
Figure GDA0003148332200000141
the preparation process comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and corn oil in the prescription amount, stirring for 2 hours at 20 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding the polyoxyethylene castor oil and the propylene glycol into the oil phase according to the prescription amount, and stirring for 2 hours at 20 ℃ to uniformly mix to form self-emulsifying concentrated solution;
(3) Preparing capsule skin by weighing gelatin, glycerol and water according to the weight ratio of 1.4-0.6;
(4) And (3) preparing the self-emulsifying concentrated solution obtained in the step (2) and the capsule shell obtained in the step (3) into soft capsules in a conventional manner.
EXAMPLE 9 preparation of pharmaceutical composition self-emulsifying Soft Capsule
The prescription of the contents:
Figure GDA0003148332200000142
the preparation process is the same as example 6.
EXAMPLE 10 preparation of self-emulsifying Soft capsules of pharmaceutical composition
Content prescription:
Figure GDA0003148332200000143
the preparation process is the same as example 6.
EXAMPLE 11 preparation of pharmaceutical composition self-emulsifying hard capsules
Content prescription:
Figure GDA0003148332200000151
the preparation process comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and soybean oil in the formula amount, and stirring for 2 hours at 20 ℃ to be uniformly mixed to obtain an oil phase;
(2) Adding the Tween 80 and the propylene glycol into the oil phase according to the prescription amount, and stirring for 2 hours at 20 ℃ to uniformly mix to form a self-emulsifying concentrated solution;
(3) And (3) dripping the self-emulsifying concentrated solution obtained in the step (2) into a proper amount of superfine silica gel powder under stirring, adding magnesium stearate, and subpackaging into hard capsules.
EXAMPLE 12 preparation of pharmaceutical composition self-emulsifying tablet
The prescription of the concentrated solution is as follows:
Figure GDA0003148332200000152
the preparation process comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and soybean oil in the prescription amount, stirring for 2 hours at 20 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding the Tween 80 and the propylene glycol into the oil phase according to the prescription amount, and stirring for 2 hours at 20 ℃ to uniformly mix to form a self-emulsifying concentrated solution;
(3) And (3) dripping the self-emulsifying concentrated solution obtained in the step (2) into a proper amount of superfine silica gel powder under stirring, adding auxiliary materials such as microcrystalline cellulose, spray-dried lactose, magnesium stearate and the like, and preparing the self-emulsifying concentrated solution from the emulsifying tablets by a conventional direct tabletting method.
Example 13: preparation of self-emulsifying soft capsule of medicinal composition
Content prescription:
Figure GDA0003148332200000161
the preparation process comprises the following steps:
(1) Taking eucalyptol, limonene and alpha-pinene in the prescription amount, stirring for 1 hour at 20 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding Tween 80 and polyethylene glycol caprylic capric acid into the oil phase, stirring at 20 deg.C for 2 hr, and mixing to obtain self-emulsifying concentrated solution;
(3) Preparing capsule skin by weighing gelatin, glycerol and water according to the weight ratio of 1;
(4) And (3) preparing the self-emulsifying concentrated solution obtained in the step (2) and the capsule shell obtained in the step (3) into soft capsules in a conventional manner.
EXAMPLE 14 preparation of self-emulsifying Soft Capsule for pharmaceutical composition
The prescription of the contents:
Figure GDA0003148332200000162
the preparation process comprises the following steps:
(1) Taking eucalyptol, limonene and alpha-pinene in the prescription amount, stirring for 1 hour at 20 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding prescription dose of caprylic/capric polyethylene glycol glyceride and polyoxyethylene castor oil into an oil phase, stirring for 2 hours at 20 ℃, and uniformly mixing to form a self-emulsifying concentrated solution;
(3) Preparing capsule skin by weighing gelatin, glycerol and water according to the weight ratio of 1;
(4) And (3) preparing the self-emulsifying concentrated solution obtained in the step (2) and the capsule shell obtained in the step (3) into soft capsules in a conventional manner.
The inventors have found that the removal of hydrophilic co-emulsifiers from the self-emulsifying concentrates of examples 13 and 14 reduces the stratification of the concentrates, facilitates the mixing of large amounts of drug, and improves the uniformity of drug content.
Comparative example 1 preparation of terpene-based pharmaceutical composition self-emulsifying Soft Capsule Using existing self-emulsifying formulation Process
According to the disclosed self-emulsifying preparation formula, the formula of the self-emulsifying medicinal liquid of the terpene medicinal composition is designed as follows:
Figure GDA0003148332200000171
the preparation method is disclosed as follows:
(1) Taking eucalyptol, limonene and alpha-pinene in the prescription amount, adding ethyl oleate, and mixing uniformly to obtain an oil phase;
(2) Mixing the Tween 80 and PEG-400 according to the prescription amount, and uniformly mixing by using a magnetic stirrer to obtain an emulsified phase;
(3) Mixing the oil phase and the emulsified phase, and uniformly mixing in a stirring, vibrating, ultrasonic or vortex mode to form self-emulsifying liquid medicine;
(4) According to the weight ratio of 1:0.45:1.1 preparing capsule skin by weighing gelatin, glycerol and water;
(5) And (4) pressing the self-emulsifying liquid medicine obtained in the step (3) and the capsule skin obtained in the step (4) on a soft capsule machine in a conventional mode, and setting in a setting machine to prepare the self-emulsifying soft capsule.
Comparative example 2 preparation of terpene-based pharmaceutical composition self-emulsifying Soft Capsule Using the existing formulation of self-emulsifying preparation and the preparation method of the present invention
According to the disclosed self-emulsifying preparation formula, the formula of the self-emulsifying medicinal liquid of the terpene medicinal composition is designed as follows:
Figure GDA0003148332200000172
the preparation method comprises the following steps:
(1) Taking eucalyptol, limonene, alpha-pinene and ethyl oleate in the formula amount, stirring at the rotating speed of 50rpm for 1 hour at 15 ℃, and uniformly mixing to obtain an oil phase;
(2) Adding Tween 80 and PEG-400 into the oil phase, stirring at 15 deg.C and 50rpm for 1 hr to obtain emulsified medicinal liquid;
(3) According to the weight ratio of 1:0.5:1.1 preparing capsule skin by weighing gelatin, glycerol and water;
(4) And (3) pressing the self-emulsifying liquid medicine obtained in the step (2) and the capsule skin obtained in the step (3) on a soft capsule machine in a conventional mode, and setting in a setting machine to prepare the self-emulsifying soft capsule.
EXAMPLE 15 Property Observation of different self-emulsifying formulations
The oil phase, the emulsifier and the co-emulsifier are respectively used as one phase, the components are fully mixed according to different proportions, the mixture is kept stand for 2 hours, and whether a uniform, transparent and non-layered solution is formed or not is observed visually. A formulation which formed a uniform, transparent solution was taken out by 0.5mL, added dropwise to 50mL of purified water at 37 ℃ with stirring at 50rpm, and observed whether a clear and transparent emulsion was formed.
The results show that: 1. the self-emulsifying liquid medicines in the comparative examples 1 and 2 are layered after standing, the self-emulsifying liquid medicine layering phenomenon of the comparative example 1 is more serious, and the self-emulsifying liquid medicines of the examples 1 to 11 of the invention are not layered after standing; 2. the self-emulsifying liquid medicines of comparative examples 1 and 2 cannot be rapidly dispersed into uniform emulsions in water, and a large number of oil droplets float on the surface of water after dispersion, and effective self-emulsification cannot be realized, whereas the self-emulsifying liquid medicines of examples 1 to 11 of the present invention can be rapidly and uniformly dispersed in water, and the formed emulsion droplets have small particle sizes and uniform particle size distribution.
It is thus understood that the self-emulsifying preparation techniques disclosed in the prior art are not easily applied directly to the terpene-based pharmaceutical composition of the present invention, and that the self-emulsifying preparations of terpene-based pharmaceutical compositions prepared according to the prior art cannot achieve a good self-emulsifying effect.
Example 16 particle size measurement of self-emulsifying Dispersion
0.5mL of the self-emulsified liquid medicines of examples 1 to 11 was dispersed in 50mL of purified water at 37 ℃, and the particle size of the emulsion droplets was measured by a laser particle sizer for 2mL of the dispersion, and the results are shown in Table 6, and a typical particle size distribution chart of the self-emulsified liquid medicine in example 1 is shown in FIG. 6. The self-emulsified concentrated solution prepared by the formulation of example 1 can be rapidly dispersed in water into a nano-sized emulsion with uniform particle size, the dispersion rate is 20-40 s, the average particle size is (161.4 + -17.6) nm, and the polydispersity index is 0.278 + -0.101.
Table 6: examples 1 to 14 self-emulsifying agent Dispersion Rate and emulsion droplet particle diameter
Figure GDA0003148332200000181
Figure GDA0003148332200000191
As can be seen from Table 6 and FIG. 6, the self-emulsifying drug solutions of examples 1 to 14 of the present invention were rapidly dispersed in water into nano-sized emulsions having uniform particle diameters, a dispersion rate of 10 to 65 seconds, an average particle diameter of 40 to 190nm, and a polydispersity of 0.150 to 0.32. The self-emulsifying liquid medicine of the examples 13 and 14 has the advantages that the dispersed particle size in water is obviously reduced, the average particle size of the examples 1 to 12 is 140 to 190nm, the particle size of the example 13 is only 100 to 110nm, the particle size of the example 14 is 40 to 50nm, the examples 13 and 14 have obviously smaller particle sizes, the medicine absorption is promoted, the adverse reaction of gastrointestinal tracts is reduced, no oil phase is used, the using amount of auxiliary materials is effectively reduced, the cost is saved, and the self-emulsifying liquid medicine can be pressed into smaller soft capsules to be convenient to swallow.
The self-emulsifying liquid medicine prepared by the invention can rapidly disperse the eucalyptol, limonene and alpha-pinene medicinal composition into the nano-emulsion, has smaller particle size, is favorable for accelerating medicament absorption and simultaneously reduces adverse reaction of gastrointestinal tracts.
Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate. Various modifications and substitutions of those details may be made in light of the overall teachings of the disclosure, and such changes are intended to be within the scope of the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an illustrative embodiment," "an example," "a specific example," or "some examples" or the like mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.

Claims (20)

1. A self-emulsifying oral formulation comprising:
active ingredients including eucalyptol, limonene and alpha-pinene; and
a carrier of a medicine, wherein the medicine is prepared from a traditional Chinese medicine,
A. the drug carrier includes:
an emulsifier;
grease; and
an auxiliary emulsifying agent is added into the mixture,
the emulsifier comprises at least one selected from tween, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil and caprylic capric polyethylene glycol glyceride;
the oil comprises at least one selected from soybean oil, medium chain triglyceride, ethyl oleate and corn oil;
the coemulsifier comprises at least one selected from 1, 2-propylene glycol, polyethylene glycol and diethylene glycol monoethyl ether,
or,
B. the drug carrier is composed of a first emulsifier and a second emulsifier, the first emulsifier is caprylic/capric polyethylene glycol glyceride, and the second emulsifier is tween or polyoxyethylene castor oil.
2. The self-emulsifying oral formulation of claim 1, wherein the self-emulsifying oral formulation comprises:
40 to 65 parts by weight of the eucalyptol;
25 to 45 parts by weight of the limonene; and
5 to 20 parts by weight of the alpha-pinene.
3. The self-emulsifying oral formulation according to claim 2, wherein the weight ratio of the active ingredient to the pharmaceutical carrier is (1-15): 10.
4. The self-emulsifying oral formulation according to claim 2, wherein the weight ratio of the active ingredient to the pharmaceutical carrier is (1-5): 10.
5. The self-emulsifying oral formulation according to claim 2, wherein the weight ratio of the active ingredient to the pharmaceutical carrier is (5-6): 10.
6. The self-emulsifying oral formulation of claim 2, wherein the weight ratio of the active ingredient to the pharmaceutical carrier is 5.4.
7. The self-emulsifying oral formulation of claim 1, wherein the pharmaceutical carrier comprises:
10 to 50 parts by weight of the oil;
40 to 80 parts by weight of the emulsifier; and
5-30 parts by weight of the co-emulsifier.
8. The self-emulsifying oral formulation of claim 1, wherein the pharmaceutical carrier comprises:
10 to 35 parts by weight of the oil;
50 to 70 of the emulsifier; and
10-25 parts by weight of the co-emulsifier.
9. The self-emulsifying oral formulation of claim 1, wherein the pharmaceutical carrier comprises:
25 to 35 parts by weight of said medium chain triglycerides;
50-65 parts by weight of the caprylic/capric polyethylene glycol glyceride; and
10 to 15 parts by weight of diethylene glycol monoethyl ether.
10. The self-emulsifying oral formulation of claim 1, wherein the pharmaceutical carrier comprises:
0 to 5 parts by weight of the oil;
0 to 5 parts by weight of the co-emulsifier;
90 to 100 parts by weight of the emulsifier.
11. The self-emulsifying oral preparation according to claim 1, wherein the first emulsifier is present in an amount of 20 to 80% by mass and the second emulsifier is present in an amount of 10 to 70% by mass, based on the total mass of the self-emulsifying oral preparation.
12. The self-emulsifying oral formulation according to any one of the preceding claims, wherein the self-emulsifying oral formulation is in the form of a hard capsule, a soft capsule or a tablet.
13. The self-emulsifying oral formulation according to any one of claims 1 to 11, comprising:
18.2g of eucalyptol, 18.2g,
16.4g of limonene, 16.4g,
1.8g of alpha-pinene,
181.8g of soybean oil,
145.4g of Tween 80, and the like,
36.4g of propylene glycol; or
73.3g of eucalyptol, and the like,
33.3g of limonene, 33.3g,
26.6g of alpha-pinene,
26.7g of a medium chain triglyceride,
213.4g of caprylic/capric macrogol glyceride,
26.7g diethylene glycol monoethyl ether; or
14.6g of eucalyptol, namely,
16.4g of limonene, 16.4g,
5.4g of alpha-pinene,
90.9g of a medium chain triglyceride,
236.6g of caprylic capric acid polyethylene glycol glyceride,
36.4g diethylene glycol monoethyl ether; or
86.6g of eucalyptol, the rest of the ingredients are added,
40.0g of limonene was added to the mixture,
6.6g of alpha-pinene,
93.4g of a medium chain triglyceride,
133.4g of caprylic/capric macrogol glyceride,
40g of diethylene glycol monoethyl ether; or
53.3g of eucalyptol, namely,
53.3g of limonene was added as a mixture,
26.6g of alpha-pinene,
26.7g of ethyl oleate are added to the solution,
160.1g of a polyoxyethylated castor oil,
80.0g of diethylene glycol monoethyl ether; or
78.0g of eucalyptol, a coarse powder,
36.0g of limonene was added to the mixture,
6.0g of alpha-pinene,
126g of corn oil, namely, corn oil,
140g of a polyoxyethylene hydrogenated castor oil,
14.0g propylene glycol; or
42.7g of eucalyptol, namely,
28.0g of limonene was added as a mixture,
9.3g of alpha-pinene,
80g of soybean oil (80 g),
180g of Tween-80 (in g),
60g of PEG-400; or
69.3g of eucalyptol, namely,
45.5g of limonene was added to the mixture,
15.2g of alpha-pinene,
40g of corn oil, namely corn oil,
170g of a polyoxyethylene castor oil,
60g of propylene glycol; or
70.0g of eucalyptol, and the like,
45.5g of limonene was added as a mixture,
14.5g of alpha-pinene,
40g of soybean oil (40 g),
180g of polyoxyethylene hydrogenated castor oil,
50g of propylene glycol; or
70.0g of eucalyptol is added,
45.5g of limonene was added to the mixture,
14.5g of alpha-pinene,
50g of ethyl oleate are added to the mixture,
160g of caprylic capric acid polyethylene glycol glyceride,
60g of diethylene glycol monoethyl ether; or
69.3g of eucalyptol, namely,
45.5g of limonene was added to the mixture,
15.2g of alpha-pinene,
40g of a soybean oil (40 g),
170g of Tween 80, and a pharmaceutically acceptable carrier,
60g of propylene glycol; or
75g of eucalyptol and a mixture of the following ingredients,
50g of a mixture of limonene and limonene,
16g of alpha-pinene, which is,
79g of Tween 80, and a stirring device,
180g caprylic capric acid polyethylene glycol glyceride; or
75g of the eucalyptus oil is added,
50g of a mixture of limonene and limonene,
16g of alpha-pinene, which is,
165g of caprylic capric acid polyethylene glycol glyceride,
94g of polyoxyethylated castor oil.
14. A process for preparing the self-emulsifying oral formulation of any preceding claim, comprising: mixing said active ingredient with said pharmaceutical carrier so as to obtain said self-emulsifying oral formulation.
15. The method of claim 14, further comprising encapsulating a mixture comprising the active ingredient and the pharmaceutical carrier to obtain a formulation.
16. The method of claim 15, wherein the formulation is a soft capsule, a hard capsule, or a tablet.
17. The method of claim 14, wherein mixing the active ingredient with the pharmaceutical carrier further comprises:
subjecting the active ingredient and optionally the fat to a first mixing treatment so as to obtain an oily phase mixture;
and carrying out second mixing treatment on the oil-phase mixture, the emulsifier and the optional coemulsifier.
18. The method according to claim 17, wherein the first mixing process and the second mixing process are each independently performed under the following conditions:
the temperature is 15-30 ℃;
the stirring speed is as follows: 30-50 rpm; and/or
The mixing time is 1 to 2 hours.
19. Use of a self-emulsifying oral formulation according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment or prevention of a respiratory disease.
20. The use according to claim 19, wherein the respiratory disease comprises: acute sinusitis, chronic sinusitis, sinusitis operation inflammation, acute and chronic bronchitis, pneumonia, bronchiectasis, lung abscess, chronic obstructive pulmonary disease, pulmonary fungal infection, pulmonary tuberculosis, and silicosis.
CN201980087982.3A 2019-01-15 2019-11-19 Self-emulsifying oral preparation of terpene medicinal composition, its preparation method and application Active CN113329736B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910036486.7A CN109528649B (en) 2019-01-15 2019-01-15 Self-emulsifying oral preparation of terpene pharmaceutical composition, preparation method and application
CN2019100364867 2019-01-15
PCT/CN2019/119346 WO2020147416A1 (en) 2019-01-15 2019-11-19 Terpene pharmaceutical composition self-emulsifying oral preparation, preparation method therefor and use thereof

Publications (2)

Publication Number Publication Date
CN113329736A CN113329736A (en) 2021-08-31
CN113329736B true CN113329736B (en) 2023-01-13

Family

ID=65835383

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910036486.7A Active CN109528649B (en) 2019-01-15 2019-01-15 Self-emulsifying oral preparation of terpene pharmaceutical composition, preparation method and application
CN201980087982.3A Active CN113329736B (en) 2019-01-15 2019-11-19 Self-emulsifying oral preparation of terpene medicinal composition, its preparation method and application

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910036486.7A Active CN109528649B (en) 2019-01-15 2019-01-15 Self-emulsifying oral preparation of terpene pharmaceutical composition, preparation method and application

Country Status (2)

Country Link
CN (2) CN109528649B (en)
WO (1) WO2020147416A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109528649B (en) * 2019-01-15 2021-06-29 北京远大九和药业有限公司 Self-emulsifying oral preparation of terpene pharmaceutical composition, preparation method and application
CN112704674B (en) * 2019-10-25 2024-03-12 北京远大九和药业有限公司 A pharmaceutical oral emulsion, and its preparation method and application
CN112791120B (en) * 2019-10-25 2023-08-01 北京远大九和药业有限公司 A pharmaceutical oral emulsion, and its preparation method and application
CN113018457B (en) * 2019-12-25 2022-09-02 北京远大九和药业有限公司 Cyclodextrin inclusion compound and preparation method thereof
CN113116856B (en) * 2019-12-31 2023-01-13 北京远大九和药业有限公司 Eucalyptus and pinene enteric-coated microspheres and preparation method thereof
CN114642635B (en) * 2020-12-18 2023-06-30 北京远大九和药业有限公司 Oral emulsion of terpene medicine composition and preparation method and application thereof
CN114796167B (en) * 2021-01-29 2023-09-29 北京远大九和药业有限公司 Inhalation preparation of terpene pharmaceutical composition and preparation method thereof
CN113068705B (en) * 2021-03-26 2021-09-28 江南大学 Preparation method of eucalyptol emulsion and application of eucalyptol emulsion in biopesticide
CN113181262B (en) * 2021-04-15 2022-07-08 江西中医药大学 Preparation for improving respiratory system diseases, pretreatment method and application
CN115887425A (en) * 2022-12-08 2023-04-04 广州国家实验室 Pharmaceutical composition, preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101254237A (en) * 2008-04-10 2008-09-03 北京九和药业有限公司 Preparation of pharmaceutical combination enteric soft capsules containing eucalyptol, limonene and a-pinene
CN101590033A (en) * 2009-07-01 2009-12-02 北京九和药业有限公司 The medicinal composition fat emulsion injection and the preparation method that contain eucalyptol, limonene and a-pinene
CN103893165A (en) * 2014-03-27 2014-07-02 北京九和药业有限公司 Nebulizer for treating respiratory system diseases
CN108078975A (en) * 2017-12-29 2018-05-29 北京九和药业有限公司 Application of the pharmaceutical composition containing eucalyptol, limonene and australene in the drug for preparing treatment upper respiratory tract bacterium infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105708797B (en) * 2014-12-05 2020-03-17 天士力医药集团股份有限公司 Self-emulsifying drug delivery system for replacing cinnamamide derivative
CN105395492B (en) * 2015-11-23 2018-05-25 河南大学 A kind of volatile oil solid self-emulsifying tablet and preparation method thereof
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-emulsifying compositions of cannabinoids
CN107929394B (en) * 2018-01-17 2021-01-26 信阳农林学院 Oral solid self-emulsifying dispersion for treating respiratory diseases of livestock and poultry
CN109528649B (en) * 2019-01-15 2021-06-29 北京远大九和药业有限公司 Self-emulsifying oral preparation of terpene pharmaceutical composition, preparation method and application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101254237A (en) * 2008-04-10 2008-09-03 北京九和药业有限公司 Preparation of pharmaceutical combination enteric soft capsules containing eucalyptol, limonene and a-pinene
CN101590033A (en) * 2009-07-01 2009-12-02 北京九和药业有限公司 The medicinal composition fat emulsion injection and the preparation method that contain eucalyptol, limonene and a-pinene
CN103893165A (en) * 2014-03-27 2014-07-02 北京九和药业有限公司 Nebulizer for treating respiratory system diseases
CN108078975A (en) * 2017-12-29 2018-05-29 北京九和药业有限公司 Application of the pharmaceutical composition containing eucalyptol, limonene and australene in the drug for preparing treatment upper respiratory tract bacterium infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Preparation and protective effects of 1,8-cineole-loaded self microemulsifying drug delivery system on lipopolysaccharide-induced endothelial injury in mice;Feng Jiang等;《European Journal of Pharmaceutical Sciences》;20181015;14-23 *

Also Published As

Publication number Publication date
CN109528649B (en) 2021-06-29
WO2020147416A1 (en) 2020-07-23
CN109528649A (en) 2019-03-29
CN113329736A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
CN113329736B (en) Self-emulsifying oral preparation of terpene medicinal composition, its preparation method and application
Talegaonkar et al. Microemulsions: a novel approach to enhanced drug delivery
EP2600838B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
EP2062571B1 (en) Self-emulsifying pharmaceutical composition with enhanced bioavailability
US20020160049A1 (en) Emulsions as solid dosage forms for oral administration
US8252326B2 (en) Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
CN107184549B (en) Nintedanib self-microemulsion preparation, soft capsule prepared from same and preparation method of soft capsule
CN104224711B (en) Paclitaxel submicron emulsion taking steroid compound as intermediate vector
EP1249230B1 (en) Microemulsion-preconcentrates and microemulsions comprising coenzyme Q10
EP1334717B1 (en) Pharmaceutical Compositions For Oral And Topical Administration
CN101703468A (en) Nano-emulsion of vitamin E oil and preparation method thereof
JPS6230965B2 (en)
CN101612121A (en) The preparation of microemulsion containing paclitaxel method
CN107921017A (en) The method treated using cadotril composition
EP1227793A1 (en) Cyclosporin formulation
EP1648517A1 (en) Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
JPH01249716A (en) Fatty emulsion of fine particle
CN114642635B (en) Oral emulsion of terpene medicine composition and preparation method and application thereof
AU2859801A (en) Pharmaceutical compositions for oral administration
WO2023278708A1 (en) Methods for treatment of pain with cannabinoids
US20060233842A1 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
US20200360286A1 (en) Self-emulsifying cannabidiol formulations
CN116920105A (en) Terpene pharmaceutical composition self-emulsifying solution and preparation method thereof
WO2023278665A1 (en) Methods for treatment of opioid use disorder with cannabinoids
JP2003261442A (en) Soft capsule preparation containing pseudoephedrine hydrochloride

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant